Anti-Mouse IFNß – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse IFNß – Purified in vivo PLATINUM™ Functional Grade
Product No.: B659
Clone HDß-4A7 Target IFNβ Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Clone HDb-4A7, Isotype Mouse IgG2a Applications B , FA , in vivo , N , WB |
Data
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Plasmid DNA encoding murine IFNb Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2828316 Additional Applications Reported In Literature ? FA B N WB In Vitro Activity of HDß-4A7 - Inhibits IFNb-induced Stat1 phosphorylation (level of inhibition is similar to that seen using anti-IFNAR1 mAb (MAR1-5A3). Blocks IFNb induction of MHC-I expression (H2-Kb) using L929 or fibrosarcoma cell lines. Neutralizes IFNb-induced antiviral activity in vitro following infection of L929 cells with VSV. In Vivo Activity of HDß-4A7 circulates with a half-life of ~ 14 days. Blocks in vivo IFNb leading to increased the lethality of mice infected with West Nile Virus (WNV), similar to susceptibility of IFNb-/- mice. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Mouse Anti-Mouse IFNß recognizes an epitope on Mouse IFNß & binds specifically to murine IFNb and does not bind murine IFNg or several different IFNa species HDb-4A7 binds both recombinant and natural forms of IFNb. This antibody was also pathogen tested and third-party certified by IDEXX BioReseach to meet the lowest mycoplasma specification and free of any viral pathogens of concern. NCBI Gene Bank ID UniProt.org Research Area Apoptosis . Cell Biology . Cell Death . Signal Transduction . Tumor Suppressors Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. In Vivo Applications of Clone HDß-4A7 in MiceClone HDß-4A7 is a monoclonal antibody specifically targeting murine interferon-beta (IFN-β), a key cytokine in the innate immune response. In vivo, this antibody is primarily used to neutralize or block IFN-β signaling in mice, enabling researchers to investigate the functional consequences of IFN-β deficiency during infection and immune challenge. Specific In Vivo Uses
Technical and Experimental Design
Summary Table: Key Applications
ConclusionsClone HDß-4A7 is a crucial tool for in vivo research in mice, primarily used to neutralize IFN-β and study its unique role in antiviral immunity and innate immune regulation. Its applications are especially valuable in viral infection models, where IFN-β's protective effects are a major focus, and in studies aiming to dissect the specific contributions of IFN-β apart from other interferons. Commonly used antibodies or proteins with HDß-4A7 (an antibody specific for murine interferon-beta, IFN-β) in the literature include:
Additional proteins and controls often included in these experiments:
In summary, anti-IFNAR1, MHC-I (H2-Kb), anti-pStat1, and various type I interferons are commonly used in concert with HDß-4A7. These combinations are employed to dissect the specificity, signaling pathways, and biological effects mediated by IFN-β in murine models. Key Findings from Clone HDß-4A7 Antibody ResearchClone HDß-4A7 is a mouse monoclonal IgG2a antibody developed to specifically target and bind murine interferon-beta (IFN-β), a key type I interferon involved in innate immunity and antiviral responses. In Vitro Functions
In Vivo Applications
Research Applications
Summary Table: Key Properties and Effects of HDß-4A7
ConclusionClone HDß-4A7 is a well-characterized, highly specific tool for studying the biological roles of mouse IFN-β, both in vitro and in vivo. Its ability to functionally neutralize IFN-β allows researchers to investigate the consequences of transient IFN-β blockade, particularly in models of viral infection and immune regulation. There are currently no published dosing regimens for the antibody clone HDß-4A7 in mouse models. Standard references specializing in in vivo antibody dosing for mice do not list recommendations or examples for this specific clone. As such, there is no authoritative guidance on how dosing of HDß-4A7 varies across different mouse strains, disease models, or experimental applications. Dosing practices for other antibody clones (e.g., checkpoint inhibitors like anti-PD-1, anti-PD-L1, anti-CTLA-4) commonly depend on:
In the absence of data for HDß-4A7, researchers typically follow the approach of starting with dose ranges and regimens established for antibodies with similar targets and purposes, then optimize for their specific experimental scenario. For new or uncharacterized antibodies, pilot titration studies and literature review of related clones are recommended. If you require a dosing regimen for HDß-4A7:
No source currently provides published protocols or variable guidelines for clone HDß-4A7 in any mouse model. References & Citations1. Oldstone, Michael B. A. et al. (2017) Proc Natl Acad Sci U S A. 114(14): 3708–3713. PubMed Technical ProtocolsCertificate of Analysis |
Formats Available
